K-Ras and mitochondria: Dangerous liaisons

Cell Research

Volumn 22, Issue 2, 2012, Pages 285-287

  Neuzil, Jiri ^a,b   Rohlena, Jakub ^b   Dong, Lan Feng ^a  

^a GRIFFITH UNIVERSITY   (Australia)

^b INSTITUTE OF BIOTECHNOLOGY   (Czech Republic)

Author keywords

[No Author keywords available]

Indexed keywords

RAS PROTEIN;

ANIMAL; ARTICLE; GLYCOLYSIS; HUMAN; METABOLISM; MITOCHONDRION; OXIDATIVE PHOSPHORYLATION;

ANIMALS; GLYCOLYSIS; HUMANS; MITOCHONDRIA; OXIDATIVE PHOSPHORYLATION; RAS PROTEINS;

EID: 84856609056     PISSN: 10010602     EISSN: 17487838     Source Type: Journal    
DOI: 10.1038/cr.2011.160     Document Type: Article

References (15)

1. Hanahan D, Weinberg RA. Hallmarks of cancer: the next generation. Cell 2011; 144:646-674
2. Jemal A, Bray F, Center MM, et al. Global cancer statistics. CA Cancer J Clin 2011; 61:69-90.
3. Balmain A, Pragnell IB. Mouse skin carcinomas induced in vivo by chemical carcinogens have a transforming Harvey-ras oncogene. Nature 1983; 303:72-74. (Pubitemid 13125077)
4. Hall A, Marshall CJ, Spurr NK, Weiss RA. Identification of transforming gene in two human sarcoma cell lines as a new member of the ras gene family located on chromosome 1. Nature 1983; 303:396-400. (Pubitemid 13094876)
5. Santos E, Martin-Zanca D, Reddy EP, et al. Malignant activation of a K-ras oncogene in lung carcinoma but not in normal tissue of the same patient. Science 1984; 223:661-664. (Pubitemid 14186799)
6. Dhillon AS, Hagan S, Rath O, Kolch W. MAP kinase signalling pathways in cancer. Oncogene 2007; 26:3279-3290. (Pubitemid 46763021)
7. Gogvadze V, Orrenius S, Zhivotovsky B. Mitochondria in cancer cells: what is so special about them? Trends Cell Biol 2008; 18:165-173.
8. Ralph SJ, Rodríguez-Enríquez S, Neuzil J, et al. The causes of cancer revisited: "mitochondrial malignancy" and ROS-induced oncogenic transformation - why mitochondria are targets for cancer therapy. Mol Aspects Med 2010; 31:145-170.
9. Weinberg F, Hamanaka R, Wheaton WW, et al. Mitochondrial metabolism and ROS generation are essential for Kras-mediated tumorigenicity. Proc Natl Acad Sci USA 2010; 107:8788-8793.
10. Vander Heiden MG, Cantley LC, Thompson CB. Understanding the Warburg effect: the metabolic requirements of cell proliferation. Science 2009; 324:1029-1033.
11. Yun J, Rago C, Cheong I, et al. Glucose deprivation contributes to the development of KRAS pathway mutations in tumor cells. Science 2009; 325:1555-1559.
12. Hu Y, Lu W, Chen G, et al. K-rasG12V transformation leads to mitochondrial dysfunction and a metabolic switch from oxidative phosphorylation to glycolysis. Cell Res 2012; 22:399-412.
13. Gough DJ, Corlett A, Schlessinger K, et al. Mitochondrial STAT3 supports Ras-dependent oncogenic transformation. Science 2009; 324:1713-1716.
14. Rohlena J, Dong L, Ralph S, Neuzil J. Anticancer drugs targeting the mitochondrial electron transport chain. Antioxid Redox Signal 2011; 15:2951-2974.
15. Dong LF, Low P, Dyason J, et al. Tocopheryl succinate induces apoptosis by targeting ubiquinone-binding sites in mitochondrial respiratory complex II. Oncogene 2008; 27:4324-4335. (Pubitemid 352010000)